Hormone therapy and ovarian cancer

All recently published studies including the MWS4 and DaHoRS have reported a greater risk of ovarian cancer with oestrogen therapy than with oestrogen and progestagen therapy, which is contradictory with the present analysis.1 The authors' statement that women who use menopausal hormone therapy...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2015-09, Vol.386 (9998), p.1038-1038
Main Authors: Trémollieres, Florence, Lopès, Patrice, Gompel, Anne
Format: Article
Language:English
Subjects:
Estrogen Replacement Therapy - adverse effects
Female
Health risk assessment
Hormone replacement therapy
Humans
Internal Medicine
Menopause
Ovarian cancer
Ovarian Neoplasms - chemically induced
Ovarian Neoplasms - epidemiology
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:All recently published studies including the MWS4 and DaHoRS have reported a greater risk of ovarian cancer with oestrogen therapy than with oestrogen and progestagen therapy, which is contradictory with the present analysis.1 The authors' statement that women who use menopausal hormone therapy for 5 years at age 50 years have one additional ovarian cancer per 1000 users is misleading and unduly alarming. Since the absolute risk of ovarian cancer is about a tenth of that of breast cancer after menopause,5 such a risk level is indefensible.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(15)00139-7